GlassScriptPhysician profile
Kristen Updegraff
NPI 1538127519
$3,627.21
in general payments reported to CMS, 2019-2025
36 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $423 · 2021: $613 · 2022: $335 · 2023: $357 · 2024: $619 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $761.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $528.59 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $320.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.85 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $201.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $190.46 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $175.05 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $117.33 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $114.40 | 2021-2025 | |
| Amarin Pharma, INC. | $113.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.88 | 2019-2021 | |
| Esperion Therapeutics, INC. | $83.21 | 2021-2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $59.96 | 2023-2024 | Quviviq |
| Dexcom, INC. | $51.59 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $49.16 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $45.42 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $40.09 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $35.27 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $31.61 | 2021-2024 | Spravato |
| Verity Pharmaceuticals INC. | $23.68 | 2025 | Tlando |
| Axonics, INC. | $21.82 | 2023 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2022 | |
| Hologic Sales and Service, LLC | $19.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.73 | 2022 | |
| Harmony Biosciences LLC | $18.52 | 2025 | |
| Merck Sharp & Dohme LLC | $18.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.42 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $16.28 | 2021 | |
| Exact Sciences Corporation | $15.61 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $14.45 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.97 | 2022 | |
| Horizon Therapeutics Plc | $13.69 | 2019 | |
| Boston Scientific Corporation | $13.44 | 2019 | |
| Hikma Pharmaceuticals USA | $13.43 | 2020 | |
| Gilead Sciences, INC. | $12.44 | 2019 | |
| Aytu Biopharma, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Updegraff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.